Nifedipine Ratiopharm

Nifedipine, the active ingredient in Nifedipine Ratiopharm, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to manage high blood pressure and certain types of chest pain in adult patients. GNH USA supplies Nifedipine Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nifedipine belongs to the calcium channel blocker class and is indicated for conditions involving vascular tone and myocardial oxygen demand. - Hypertension: lowers systemic blood pressure by relaxing arterial smooth muscle. - Angina pectoris: reduces cardiac workload and oxygen consumption, relieving chest pain. - Coronary artery disease: improves coronary blood flow and helps prevent ischemic episodes.

Nifedipine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warmth and redness of the skin. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness. - Nausea or abdominal discomfort. - Palpitations or tachycardia.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare but possible cardiac event. - Life‑threatening arrhythmias. - Hepatic dysfunction or jaundice. - Allergic reactions including rash, angioedema, or anaphylaxis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider the following safety measures. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Cardiac assessment: evaluate for recent myocardial infarction or unstable angina. - Hepatic function: adjust use in patients with significant liver impairment. - Concomitant antihypertensives: watch for additive hypotensive effects. - Abrupt discontinuation: taper to prevent rebound hypertension. - Store at below 25°C: keep in the original pack, protect from moisture.

Nifedipine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of toxicity. - Grapefruit juice: can markedly raise nifedipine levels. - Strong CYP3A inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: additive blood‑pressure lowering effect. - Diuretics: may enhance hypotensive response. - Antacids containing aluminum or magnesium: could affect absorption if taken simultaneously.